О компании

GenEdit, Inc. focuses on the development of novel, non-viral, nanoparticle-based delivery technology and enabling next generation CRISPR-based gene therapies. The foundation of our CRISPR-Nanoparticle Technology Platform is based on successfully engineering the individual components of the CRISPR system to overcome the limitations of existing delivery vehicles for CRISPR-based therapeutics.

US
Неизвестно
Не проверенная компания